Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

April W Armstrong

Showing results (391-400 of 434) with videos related to

Pageof 44
Sort By:
Journal of the American Academy of Dermatology|November 19, 2025
Joint position statement from the National Psoriasis Foundation Medical Board and the International Psoriasis Council on routine testing for latent tuberculosis infection prior to and during treatment of psoriasis patients with interleukin 17 or interleukin 23 inhibitorsAndrew Blauvelt, Bruce E Strober, Guy S Eakin, et al.
The Journal of Rheumatology|February 16, 2021
Proceedings of the 2020 GRAPPA Collaborative Research Network (CRN) MeetingCarmel Stober, Deepak R Jadon, April W Armstrong, et al.
JAMA Dermatology|November 27, 2024
Safety and Efficacy of Deucravacitinib in Moderate to Severe Plaque Psoriasis for Up to 3 Years: An Open-Label Extension of Randomized Clinical TrialsApril W Armstrong, Mark Lebwohl, Richard B Warren, et al.
The New England Journal of Medicine|December 8, 2021
Phase 3 Trials of Tapinarof Cream for Plaque PsoriasisMark G Lebwohl, Linda Stein Gold, Bruce Strober, et al.
The British Journal of Dermatology|August 28, 2025
SPECTREM Phase 3b Clinical Trial Results Through Week 16: Guselkumab Efficacy and Safety for the Treatment of Low Body Surface Area, Moderate Psoriasis With High-Impact Site InvolvementLinda Stein Gold, Alice B Gottlieb, April W Armstrong, et al.
Acta Dermato-Venereologica|June 11, 2026
Efficacy and Safety of Nemolizumab at Week 48: Results from the Maintenance Phase of Two Global Phase 3 Pivotal Studies (ARCADIA 1&2) in Patients with Moderate-to-Severe Atopic DermatitisAndreas Wollenberg, Jonathan I Silverberg, Franz J Legat, et al.
The Journal of Rheumatology|April 2, 2022
Proceedings of the 2021 GRAPPA-Collaborative Research Network (CRN) MeetingCarmel Stober, Iain B McInnes, Soumya Raychaudhuri, et al.
Dermatologic Surgery : Official Publication for American Society for Dermatologic Surgery [Et Al.]|March 5, 2019
Assessing Skin Biopsy Rates for Histologic Findings Indicative of Nonpathological Cutaneous DiseaseJames A Solomon, Michael Oswalt, Michael Nodzenski, et al.
Allergy|December 18, 2023
Effect of abrocitinib on skin biomarkers in patients with moderate-to-severe atopic dermatitisEmma Guttman-Yassky, Paola Facheris, Pedro Jesus Gomez-Arias, et al.
Journal of the American Academy of Dermatology|July 26, 2023
Sociodemographic and clinical characteristics associated with multiple biologic failure in psoriasis: A 2015-2022 prospective cohort analysis of the CorEvitas psoriasis registryJoy Q Jin, Angel Cronin, Carla Roberts-Toler, et al.
Pageof 44

Showing results (391-400 of 434) with videos related to

Sort By:
Pageof 44
Journal of the American Academy of Dermatology|November 19, 2025
Joint position statement from the National Psoriasis Foundation Medical Board and the International Psoriasis Council on routine testing for latent tuberculosis infection prior to and during treatment of psoriasis patients with interleukin 17 or interleukin 23 inhibitorsAndrew Blauvelt, Bruce E Strober, Guy S Eakin, et al.
The Journal of Rheumatology|February 16, 2021
Proceedings of the 2020 GRAPPA Collaborative Research Network (CRN) MeetingCarmel Stober, Deepak R Jadon, April W Armstrong, et al.
JAMA Dermatology|November 27, 2024
Safety and Efficacy of Deucravacitinib in Moderate to Severe Plaque Psoriasis for Up to 3 Years: An Open-Label Extension of Randomized Clinical TrialsApril W Armstrong, Mark Lebwohl, Richard B Warren, et al.
The New England Journal of Medicine|December 8, 2021
Phase 3 Trials of Tapinarof Cream for Plaque PsoriasisMark G Lebwohl, Linda Stein Gold, Bruce Strober, et al.
The British Journal of Dermatology|August 28, 2025
SPECTREM Phase 3b Clinical Trial Results Through Week 16: Guselkumab Efficacy and Safety for the Treatment of Low Body Surface Area, Moderate Psoriasis With High-Impact Site InvolvementLinda Stein Gold, Alice B Gottlieb, April W Armstrong, et al.
Acta Dermato-Venereologica|June 11, 2026
Efficacy and Safety of Nemolizumab at Week 48: Results from the Maintenance Phase of Two Global Phase 3 Pivotal Studies (ARCADIA 1&2) in Patients with Moderate-to-Severe Atopic DermatitisAndreas Wollenberg, Jonathan I Silverberg, Franz J Legat, et al.
The Journal of Rheumatology|April 2, 2022
Proceedings of the 2021 GRAPPA-Collaborative Research Network (CRN) MeetingCarmel Stober, Iain B McInnes, Soumya Raychaudhuri, et al.
Dermatologic Surgery : Official Publication for American Society for Dermatologic Surgery [Et Al.]|March 5, 2019
Assessing Skin Biopsy Rates for Histologic Findings Indicative of Nonpathological Cutaneous DiseaseJames A Solomon, Michael Oswalt, Michael Nodzenski, et al.
Allergy|December 18, 2023
Effect of abrocitinib on skin biomarkers in patients with moderate-to-severe atopic dermatitisEmma Guttman-Yassky, Paola Facheris, Pedro Jesus Gomez-Arias, et al.
Journal of the American Academy of Dermatology|July 26, 2023
Sociodemographic and clinical characteristics associated with multiple biologic failure in psoriasis: A 2015-2022 prospective cohort analysis of the CorEvitas psoriasis registryJoy Q Jin, Angel Cronin, Carla Roberts-Toler, et al.
Pageof 44